Effect of high-intensity statin preloading on TIMI flow in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Ahmed Shawky Elserafy, Nabil Mahmoud Farag, Ahmed Ibrahim El Desoky, Khaled Adel Eletriby, Ahmed Shawky Elserafy, Nabil Mahmoud Farag, Ahmed Ibrahim El Desoky, Khaled Adel Eletriby

Abstract

Background: Acute ST-elevation myocardial infarction (STEMI) is a major cause of morbidity and mortality worldwide. Primary percutaneous coronary intervention (PCI) has improved the outcomes from STEMI and improved myocardial perfusion. However, there is still room for medical therapy to help perfuse the myocardium. The aim of this study was to assess the impact of high-intensity statins used prior to primary PCI in patients presenting with acute STEMI on myocardial perfusion. The study included 170 patients who presented with acute STEMI to Ain Shams University Hospitals and underwent primary percutaneous coronary intervention (PCI). They were divided into two groups where the first group received high-intensity statins (80 mg of atorvastatin or 20 mg of rosuvastatin) besides guideline-recommended therapy before primary PCI and the second group served as a control group and received guideline-recommended therapy, and high-intensity statins were given as usual after going back to the coronary care unit after primary PCI. Post-interventional thrombolysis in myocardial infarction (TIMI) flow grade and myocardial blush grade (MBG) were recorded, and ST-segment resolution was measured.

Results: The LAD was the culprit vessel for the majority of patients in both groups. In the control group, there were 4 patients with TIMI I flow and MBG I, 13 with TIMI II flow and MBG II, and 68 with TIMI III flow and MBG III. Meanwhile, in the cases group, there was 1 patient with TIMI I flow and MBG I, 3 with TIMI II flow and MBG II, and 81 with TIMI III flow and MBG III. This difference was statistically significant with a P value of 0.010. There were 34 patients in the cases group who showed complete ST-segment resolution (40%) vs. 19 patients (22.4%) in the control group which was statistically significant with a P value of 0.013. In addition, ejection fraction had values of mean ± SD of 45.91 ± 5.49 in the cases group vs. 43.01 ± 8.80 in the control group which was statistically significant with a P value of 0.011.

Conclusion: High-intensity statin loading before primary PCI resulted in improved post-procedural TIMI flow, MBG, complete ST-segment resolution, and ejection fraction.

Keywords: High-intensity statins; MBG; Myocardial blush grade; Primary PCI; STEMI; Statins; TIMI flow.

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. Park K. Coronary heart disease. In: Park’s text book of preventive and social medicine, 22nd edition, M/S Banarasidas Bhanot, Jabalpur. 2005, 339.
    1. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91:1659–1668.
    1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2011;32:2999–3054. doi: 10.1093/eurheartj/ehr236.
    1. Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented? Heart. 2010;96:736–740. doi: 10.1136/hrt.2009.186189.
    1. Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(suppl 1):3–9. doi: 10.2165/1153644-S0-000000000-00000.
    1. Arca M, Gaspardone A. Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events. Drugs. 2007;67(suppl 1):29–42. doi: 10.2165/00003495-200767001-00004.
    1. Briel M, Studer M, Glass TR, et al. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2004;117:596–606. doi: 10.1016/j.amjmed.2004.04.022.
    1. Van’t Hof AW, Liem A, de Boer MJ, et al. Myocardial Infarction Study Group. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. The Lancet. 1997;350(9078):615–619. doi: 10.1016/S0140-6736(96)07120-6.
    1. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130. doi: 10.1161/01.CIR.101.2.125.
    1. Henriques J, Zijlstra F, Van’t Hof A, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003;107:2115–2119. doi: 10.1161/01.CIR.0000065221.06430.ED.
    1. Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol. 2008;13(3):121–128.
    1. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv. 2010;3(5):332–339. doi: 10.1016/j.jcin.2009.11.021.
    1. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. JACC. 2009;54(23):2157–2163. doi: 10.1016/j.jacc.2009.07.005.
    1. Berwanger O, Santucci EV, de Barros, et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI Randomized Clinical Trial. JAMA 2018; 319:1331-1340.
    1. Ray KK, Cannon CP, McCabe CH, et al. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. JACC. 2005;46(8):1405–1410. doi: 10.1016/j.jacc.2005.03.077.
    1. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS Randomized Trial. JACC. 2007;49(12):1272–1278. doi: 10.1016/j.jacc.2007.02.025.
    1. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) Randomized Trial. JACC. 2009;54(6):558–565. doi: 10.1016/j.jacc.2009.05.028.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere